Ultrastructural Alterations of Liver Tissue Cells in Methotrexate-Treated Balb/c Mice

Ebru Gokalp Ozkorkmaz, Nursel Gul, Aydin Ozluk, Yusuf Ozay

Department of Nursing, Faculty of Health Sciences, Ankara Yildirim Beyazit University, #Department of Biology, Faculty of Science, Ankara University, Ankara,
#Department of Biology, Faculty of Science and Art, Hitit University, Corum, #Department of Medical Biology, Faculty of Medicine, Adiyaman University, Adiyaman, Turkey

Abstract

Aim: The current study investigated the efficacy of methotrexate (MTX) on liver tissue cells of Balb/c mice at the ultrastructural level using transmission electron microscopy. Background: This agent is well known and used as a chemotherapeutic agent for a long time and not selective for cancer cells so, healthy cells beside cancer cells are also affected by MTX. Materials and Methods: Experimental animals were divided into two groups; the first group was kept without treatment and served as the control, the second group was treated with 115 mg/kg MTX i.p. once weekly for 4 weeks and sacrificed under anesthesia after the 4th week. The liver tissues were osmium fixed and embedded in araldite, sectioned and observed under transmission electron microscope. Results: Normal cell ultrastructure was determined in the control group whereas the liver cells of the MTX-treated group revealed ultrastructural alterations, such as the increase in lipid droplets, discontinuity of rough endoplasmic reticulum cisternae and vacuole formation. In addition, the loss of cytoplasmic material in hepatocytes was also evident. Condensation of nuclear chromatin and fusion of nuclear membranes were observed in the liver cells of the treated group. Conclusions: Results of the study indicated that MTX, used for different types of medical treatment, disturbed liver cell ultrastructure.

Keywords: Hepatocyte, liver, methotrexate, transmission electron microscope, ultrastructure

INTRODUCTION

Methotrexate (MTX) is a folic acid antagonist and plays a cytotoxic role in the cell cycle, inhibits DNA synthesis, stops cell proliferation, and leads cell to apoptotic death. It is well known and used as a chemotherapeutic agent for a long time and not selective for cancer cells. Healthy cells and cancer cells are affected by methotrexate (MTX).[2] MTX is also used in the treatment of psoriatic arthritis,[3] rheumatoid arthritis,[4] Crohn’s disease, and colitis.[5] MTX causes several deficits in different organs and systems.[6,7] Pinkerton et al. reported that MTX showed jejunal crypt abnormalities in children with acute lymphoblastic leukemia.[8] A study in the small intestine of rats revealed proliferation, differentiation, and cell death in goblet and paneth cells.[9] Yuncu and Kanter determined that MTX induced mucosal damage in the small intestine of mice.[10] Another study in MTX-treated intestines by Elbakary et al. detected ultrastructural changes in the form of dilation of rough endoplasmic reticulum (rER) cisternae, vacuolation of the cytoplasm, focal accumulation of lipid droplets, swollen mitochondria with destroyed cristae, short sparse microvilli with focal loss of microvillus border, widening of the intercellular space, indentation of nuclei, and variable degrees of corrugation in nuclear membrane.[11] Al-Ali et al. determined ultrastructural changes in rat livers perfused in vitro and in vivo with high doses of MTX, such as disorganized endoplasmic reticulum, dispersion of polyribosomes, a variety of mitochondrial changes, and glycogen redistribution.[12] Soliman also reported tissue damage in thin sections of MTX-treated liver such as severe degeneration of cell organelles, especially in mitochondria and rER.[13] Hepatotoxicity and hematologic toxicities were seen in patients using MTX.[14] It was mentioned that these effects resulted from binding to the enzyme dihydrofolic reductase, preventing the conversion of folic acid to its active form, folinic acid. Thus, nucleic acid and amino acid synthesis are blocked, and protein production is affected. Electron microscopic

Access this article online

Quick Response Code: [QR Code Image]
Website: http://www.jmau.org/
DOI: 10.4103/JMAU.JMAU_31_18

How to cite this article: Ozkorkmaz EG, Gul N, Ozluk A, Ozay Y. Ultrastructural alterations of liver tissue cells in methotrexate-treated Balb/c Mice. J Microsc Ultrastruct 2018;6:192-6.

Address for correspondence: Dr. Ebru Gokalp Ozkorkmaz, Faculty of Health Sciences, Yildirim Beyazit University, Ankara, Turkey. E-mail: egozkorkmaz@ybu.edu.tr

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com
observations of Choi et al. detected vesiculation and dilation of cisternae in the endoplasmic reticulum and Golgi complex, appearance of autophagic vacuoles, and, hyperplasia in pancreatic acinar cells. As a result, organelles and plasma membranes of hepatic cells are damaged and hepatic function is corrupted. Sargin et al. also stated that MTX impaired mouse kidney cell structure.

As shown, a number of studies have collected evidence for MTX-mediated tissue damage. Therefore, the present study was planned to reflect the changes in liver cells exposed to high dose of MTX in Balb/c mice.

**Materials and Methods**

**Experimental animals**

This study was performed with the permission of ethical commission of Ahi Evran University, Kırşehir, Turkey. As Balb/c mice are widely used in oncological research, they (n = 10) were preferred in the study. Mice were maintained under controlled conditions of light (12:12 h; light: dark), temperature (22°C ± 3°C), and humidity (65%). Before assays, animals were quarantined for 10 days and then divided into two groups: control group (n = 5) and MTX-treated group (n = 5).

**Methotrexate administration**

A dosage of (115 mg/kg) physiological saline solution was administered to the control group by intraperitoneal injection. Methotrexate Ebewe (MTX) (Sandoz Drug Company, Istanbul, Turkey) was injected in the same dosage of 115 mg/kg i.p. once weekly for 4 weeks to the treated group. After 4 weeks, mice were sacrificed under pentobarbital anesthesia (i.p.) overdose (>120 mg/kg).

**Transmission electron microscope preparation**

Liver tissues were removed and immersed in 2.5% glutaraldehyde buffered to pH 7.4 with 0.1 M sodium phosphate and held for 2 h for the first fixation. After rinsing with sodium phosphate buffer, tissues were postfixed in 1% osmium tetroxide solution for 2 h. Tissues were dehydrated in a series of graded ethanols, placed into propylene oxide, and embedded in araldite. Tissues were cut with an ultramicrotome to ultrathin sections of 60–80 nm and stained with uranyl acetate and lead citrate and then examined under transmission electron microscope (TEM, JEOL 100 CXII, JEOL Company, USA) at 80–100 kV in Electron Microscope Laboratories of Ankara University, Department of Biology, Faculty of Science.

**Results**

Ultrastructural investigations of the control group liver revealed a normal histological appearance. Polygonal-shaped hepatocytes with centrally localized nuclei, sinusoids, and bile canaliculus were observed in liver tissue sections [Figure 1].

MTX-treated livers removed at the end of 4 weeks displayed structural deformations in hepatocytes and irregular-shaped erythrocytes in the sinusoid. Hepatocytes contained lipid droplets, loss of cytoplasmic material, and pyknotic nuclei [Figure 2].

Due to effects of MTX, lipid droplets were seen to be numerous in hepatocytes. In addition, neutrophils were present in the hepatic sinusoid [Figure 3]. Lipid droplets and hyalinization of cytoplasmic material in cell cytoplasm were distinctive features in the MTX-treated group [Figure 4].

Most hepatocytes had a centrally placed single nucleus, but a binucleated hepatocyte was seen in this micrograph. One of the structural alterations of MTX was the fusion of nuclear membranes in the hepatocyte. In addition to this cellular disorder, cytoplasmic material loss and melting of chromatin material were seen. Note the irregular-shaped mitochondria in hepatocytes [Figure 5].

Another conspicuous finding in this group was the difference in the appearance of the hepatocyte nucleus such as chromatin clumping. Cytoplasmic material melting around the nuclear envelope was also observed [Figure 6]. Furthermore, discontinuous RER cisternae were seen among the mitochondria, which are different in size due to the effect of MTX. Abundant hepatic sinusoids were determined in treated liver [Figure 7].

**Discussion**

MTX is a therapeutic agent widely used to treat chronic inflammatory and neoplastic diseases. In the present study, ultrastructural pathological lesions, which altered the cell structure, were determined in the liver tissues of MTX-treated mice. In his study, Al-Motabagani reported that there were focal areas of liver cell necrosis with abnormal hepatic structures in MTX-treated adult male albino rats. Glycogen content was seen to decrease. Similar data were observed in the current study. Yuncu and Kanter mentioned that MTX
caused swelling in mitochondria and dilation of endoplasmic reticulum in mouse small intestine mucosa.\cite{10} Contrary to these data, we observed shrinkage of mitochondria and no dilatation but discontinuity in the endoplasmic reticulum. Choi et al. determined dilatation in endoplasmic reticulum of rat pancreatic acinar cells;\cite{15} however, we did not observe dilatation in the endoplasmic reticulum of hepatocytes. They also reported that there were no alterations in the nuclei of pancreatic acinar cells of MTX-treated rats. In contrast to this study, our data showed alterations in nuclei of MTX-treated mice, such as both melting and clumping of chromatin material and fusion of the nuclear membrane. In another study, numerous vacuoles were present in MTX-treated mouse kidneys.\cite{8} It was shown that paneth cells showed striking structural alterations with vacuolar dilatation of the cytoplasm.\cite{8} As can be seen from literature, MTX causes different changes in different tissues in terms of cell ultrastructure. If we look again at liver tissue, Al-Ali et al. introduced MTX at a dose of 0.5 mg/kg to rat livers perfused \textit{in vitro} and \textit{in vivo} and examined under electron microscope.\cite{12} TEM studies revealed disorganized endoplasmic reticulum, dispersion of the polyribosomes, a variety of mitochondrial changes, and glycogen redistribution. In addition to these findings, Soliman concluded that MTX treatment gives rise to the degeneration of liver cell organelles, especially in mitochondria and rER.\cite{13} We described similar observations in the present study such as the disruption of rER and change in the distribution of nuclear chromatin. Al-Motabagani introduced MTX to adult male rats and examined by light microscopy.\cite{16} According to
their observations, mononuclear cell infiltration was present in MTX-treated livers. Even though their observations were at the light microscopy level, their findings shed light on ours as we noticed neutrophil cells in the hepatic sinusoids as well. The presence of this type of cells suggests pinocytotic activity in order to destroy the effects of MTX. Hall et al. and Patel et al. indicated that high doses of MTX therapy (200/150/100 µg/kg and 0.250 mg/kg, respectively) can cause hepatotoxicity.\cite{21,22} We used 115 mg/kg of MTX in our study and determined that MTX has toxicological effects on hepatocytes of Balb/c mice. High doses of MTX treatment seem to cause hepatotoxicity, and a consequence of changes in the histology of the mice liver is consistent with previous studies.\cite{21,22} These findings may be a sign of the metabolizing process of degenerative effects of MTX on Balb/c mouse hepatocytes precisely because Balb/c mice are known as sensitive to carcinogens and play an important role in oncological researches. Another study presented vacuolation and degeneration of hepatocytes in MTX-administered rats.\cite{23} A study of Asci et al. found out that MTX has a direct effect on the liver structure alterations and causes cytotoxicity of hepatocytes with vacuolation of hepatic cytoplasm.\cite{24} Similarly, in different tissue, Elbakary et al. described rarefied and vacuolated cytoplasm, focal accumulation of lipid droplets, and swollen mitochondria in their assay on MTX-mediated tissue damage of intestine.\cite{11} Similar to the findings above, we also determined changes in the structure of mouse liver cells treated with MTX, such as vacuolation and degeneration in the meaning of cytoplasmic material loss. It was mentioned that MTX treatment leads to nuclear variability in liver cells\cite{25} and also indented the nucleus in enterocytes.\cite{11} Consequently, we made the same observations such as nuclear alterations in cells of the liver, such as melting and clumping of chromatin material. As MTX reduces cell proliferation, we suggest that these alterations in liver cell nuclei may be explained by the antimitotic effect of MTX. However, Quintin et al.\cite{26} revealed that the direct role of long-term low-dose MTX in the genesis of a MTX-specific liver change with dystrophic nuclei in hepatocytes was very rarely observed. On the other hand, Kremer et al.\cite{27} revealed that, even at low doses, MTX is associated with hepatic disorders like elevated liver enzymes. It should not be an unpredictable state that we expect cellular changes related with the rise of enzymes.

We hope that our findings shed light on understanding the mechanism of this multipurpose drug.

**Conclusion**

The present study examined the ultrastructural changes of liver cells in high-dose MTX-treated Balb/c mice. When all observations were evaluated, we can suggest that, despite the chemotherapeutic properties of MTX, it seems to alter liver tissue cells destructively. We think that this finding generates a biological significance as well.

**Acknowledgments**

The authors would like to thank the participants of 36th FEBS Congress, which was held in Torino, Italy. The authors also wish to thank Tugba Endogan from METU for technical support.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: Are routine biopsies really necessary? Am J Clin Dermatol 2005;6:357-63.
2. Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ,
Cummins AG, et al. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002;47:2751-7.

3. Wollina U, Ständer K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis – Short- and long-term toxicity in 104 patients. Clin Rheumatol 2001;20:406-10.

4. Padeh S, Sharon N, Schiby G, Rechavi G, Passwell JH. Hodgkin’s lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997;24:2055-7.

5. Siegel CA, Sands BE. Review article: Practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005;22:1-6.

6. Sargın AK, Oguz EO, Can B, Saran Y. Morphological alterations of methotrexate in mouse kidney. Anadolu Univ J Sci Technol 2009;10:197-203.

7. Isk A, Islay L, Aatabeni Erdemli E, Akbay C, Anafarta K. Methotrexate effects on rat testis tissue using light and electron microscope. Ankara Üniv Tıp Fakültesi Derg 1997;50:125-9.

8. Pinkerton CR, Cameron CH, Sloan JM, Glasgow JF, Gwevava NJ. Jejunal crypt abnormalities associated with methotrexate treatment in children with acute lymphoblastic leukaemia. J Clin Pathol 1982;35:1272-77.

9. Verburg M, Renes IB, Taminiau JA, Büller HA, Einerhand AW, et al. Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol 2000;279:G1037-47.

10. Yuncu M, Kanter M. Protective effect of Vitamin E against methotrexate-induced mucosal damage of the small intestine in mice: An electron microscopic study. Tıp Araştırmaları Derg 2006;4:1-6.

11. Elbakary NA, Soliman GM, Tawfik SM, Zaher SM. Evaluation of the possible protective role of Vitamin A on methotrexate-induced changes on the jejunal mucosa of adult male albino rat: Histological and immunohistochemical study. J Microsc Ultrastr 2014;2:77-93.

12. Al-Ali SY, Hassan IM, Sadek S. Ultrastructural changes in rat livers perfused in vitro and in vivo with a high dose of methotrexate. Histol Histopathol 2005;20:1131-45.

13. Soliman ME. Evaluation of the possible protective role of folic acid on the liver toxicity induced experimentally by methotrexate in adult male albino rats. Egypt J Histol 2009;3:118-28.

14. Yalniz E, Komurcuoglu B, Gurbuz S, Celikten EP. Pulmonary involvement in a patient with psoriasis due to methotrexate therapy. Turkish Thoracic Journal 2003;4:179-82.

15. Choi HY, Kim CS, Lee YB. The effects of methotrexate on the pancreas of rats. A histochemical and ultrastructural study. Yonsei Med J 1969;10:117-21.

16. Al-Motabagani MH. Histological and histochemical studies on the effects of methotrexate on the liver of adult male albino rat. Int J Morphol 2006;24:417-22.

17. Boullata J, Armenti VT. Handbook of Drug and Nutrient Interactions. USA: Humana Press; 2010.

18.Recommended Methods of Anesthesia, Analgesia, and Euthanasia for Laboratory Animal Species. Albert Einstein College of Medicine Institute for Animal Studies Van Etten Anesthesia, Analgesia, and Euthanasia. Available from: http://www.einstein.yu.edu/uploadedFiles/administration/animal-studies. [Last accessed on 2017 Aug 11].

19. Hayat MA. Principles and Techniques of Electron Microscopy, Biological Applications. Cambridge: Cambridge University Press; 2000.

20. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-104.

21. Hall PD, Jenner MA, Ahern MJ. Hepatotoxicity in a rat model caused by orally administered methotrexate. Hepatology 1991;14:906-10.

22. Patel NN, Ghodasara DJ, Pandey S, Ghodasara PD, Khorajiya JH, Joshi BP, et al. Subacute toxicopathological studies of methotrexate in Wistar rats, Vet World 2014;7:489-95.

23. Vaghasiya J, Bhalodia Y, Rathod S. Drug induced hepatotoxicity: Effect of polyherbal formulation. Pheog Mag 2009;5:232-237.

24. Asci H, Ozer MK, Calapoglu M, Savran M, Oncu M, Yesilot S, et al. Effects of misoprostol on methotrexate induced hepatic and renal damages. J Biol Life Sci 2011;2:32-7.

25. Raghunathan D, Kurady LB, Ramachandra B. Effect of methotrexate on AgNOR count in liver of Wistar rats. Iran J Pharmcol Ther 2009;8:11-5.

26. Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 2010;12:R143.

27. Kremer JM, Alarcón GS, Lightfoot RW Jr., Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.